BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hall G, Kurosawa S, Stearns-Kurosawa DJ. Shiga Toxin Therapeutics: Beyond Neutralization. Toxins (Basel) 2017;9:E291. [PMID: 28925976 DOI: 10.3390/toxins9090291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Luz D, Amaral MM, Sacerdoti F, Bernal AM, Quintilio W, Moro AM, Palermo MS, Ibarra C, Piazza RMF. Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo. Toxins (Basel) 2018;10:E508. [PMID: 30513821 DOI: 10.3390/toxins10120508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Detzner J, Pohlentz G, Müthing J. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2020;12:E373. [PMID: 32512916 DOI: 10.3390/toxins12060373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Taverner A, MacKay J, Laurent F, Hunter T, Liu K, Mangat K, Song L, Seto E, Postlethwaite S, Alam A, Chandalia A, Seung M, Saberi M, Feng W, Mrsny RJ. Cholix protein domain I functions as a carrier element for efficient apical to basal epithelial transcytosis. Tissue Barriers 2020;8:1710429. [PMID: 31928299 DOI: 10.1080/21688370.2019.1710429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Luz D, Gómez FD, Ferreira RL, Melo BS, Guth BEC, Quintilio W, Moro AM, Presta A, Sacerdoti F, Ibarra C, Chen G, Sidhu SS, Amaral MM, Piazza RMF. The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody. Toxins (Basel) 2021;13:825. [PMID: 34822608 DOI: 10.3390/toxins13110825] [Reference Citation Analysis]
5 Detzner J, Klein AL, Pohlentz G, Krojnewski E, Humpf HU, Mellmann A, Karch H, Müthing J. Primary Human Renal Proximal Tubular Epithelial Cells (pHRPTEpiCs): Shiga Toxin (Stx) Glycosphingolipid Receptors, Stx Susceptibility, and Interaction with Membrane Microdomains. Toxins (Basel) 2021;13:529. [PMID: 34437399 DOI: 10.3390/toxins13080529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jefferies D, Khalid S. To infect or not to infect: molecular determinants of bacterial outer membrane vesicle internalization by host membranes. Journal of Molecular Biology 2020;432:1251-64. [DOI: 10.1016/j.jmb.2020.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lee Y, Kim MH, Alves DR, Kim S, Lee LP, Sung JH, Park S. Gut-Kidney Axis on Chip for Studying Effects of Antibiotics on Risk of Hemolytic Uremic Syndrome by Shiga Toxin-Producing Escherichia coli. Toxins (Basel) 2021;13:775. [PMID: 34822559 DOI: 10.3390/toxins13110775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pierzynowska K, Jasińska W, Cyske Z, Bunikowska M, Droczek R, Węgrzyn G. Effects of some commonly used drinks on induction of Shiga toxin-converting prophage in Escherichia coli. J Consum Prot Food Saf 2018;13:125-9. [DOI: 10.1007/s00003-018-1155-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Barbier J, Gillet D. Ribosome Inactivating Proteins: From Plant Defense to Treatments against Human Misuse or Diseases. Toxins (Basel) 2018;10:E160. [PMID: 29669991 DOI: 10.3390/toxins10040160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Warr AR, Kuehl CJ, Waldor MK. Shiga toxin remodels the intestinal epithelial transcriptional response to Enterohemorrhagic Escherichia coli. PLoS Pathog 2021;17:e1009290. [PMID: 33529199 DOI: 10.1371/journal.ppat.1009290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Goldstein J, Nuñez-Goluboay K, Pinto A. Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli. Curr Neuropharmacol 2021;19:24-44. [PMID: 32077828 DOI: 10.2174/1570159X18666200220143001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Reference Citation Analysis]
13 Torres AG, Amaral MM, Bentancor L, Galli L, Goldstein J, Krüger A, Rojas-Lopez M. Recent Advances in Shiga Toxin-Producing Escherichia coli Research in Latin America. Microorganisms 2018;6:E100. [PMID: 30274180 DOI: 10.3390/microorganisms6040100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
14 Vind AC, Genzor AV, Bekker-Jensen S. Ribosomal stress-surveillance: three pathways is a magic number. Nucleic Acids Res 2020;48:10648-61. [PMID: 32941609 DOI: 10.1093/nar/gkaa757] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
15 Lu Z, Liu Z, Li X, Qin X, Hong H, Zhou Z, Pieters RJ, Shi J, Wu Z. Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli. ACS Infect Dis 2022. [PMID: 35015516 DOI: 10.1021/acsinfecdis.1c00456] [Reference Citation Analysis]